首页> 美国卫生研究院文献>Oncology Letters >Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer
【2h】

Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer

机译:图像导向酶靶向放射增敏和术中放疗治疗局部晚期不可切除胰腺癌的安全性和有效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A novel radiosensitization treatment involving the injection of hydrogen peroxide and sodium hyaluronate, using ultrasonic guidance, into a tumor immediately prior to intraoperative radiotherapy (IORT) was established for patients with stage IVa locally advanced unresectable pancreatic cancer. The aim of the present study was to assess the safety and efficacy of this novel treatment, termed Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas-IORT (KORTUC and IORT). In total, 12 patients were treated with KORTUC-IORT, external-beam radiotherapy and systemic chemotherapy using gemcitabine hydrochloride and S-1. For evaluation of the therapeutic and adverse effects, contrast-enhanced computed tomography was conducted prior to the treatment, and one and six months following KORTUC-IORT. Medical examinations were performed every month at the regularly scheduled follow-up visits. The one- and two-year survival rates were 75 and 25%, respectively, and the median survival time was 16 months. All treatments associated with KORTUC-IORT were well-tolerated by the patients, with a small number of adverse effects and no serious complications. It was identified that the delivery of KORTUC-IORT is safe and effective, in combination with external-beam radiotherapy and systemic chemotherapy, for patients with locally advanced unresectable pancreatic cancer.
机译:对于患有IVa期局部晚期无法切除的胰腺癌的患者,已建立了一种新的放射增敏治疗方法,其中涉及在术中放疗(IORT)之前立即使用超声引导将过氧化氢和透明质酸钠注射入肿瘤。本研究的目的是评估这种不可治愈的癌-IORT(KORTUC和IORT)新疗法的安全性和有效性。共有12例患者接受了盐酸吉西他滨和S-1的KORTUC-IORT,束外放疗和全身化疗的治疗。为了评估治疗效果和不良反应,在治疗前以及KORTUC-IORT后1个月和6个月进行了对比增强计算机断层扫描。在定期安排的随访中每月进行一次体检。一年和两年生存率分别为75%和25%,中位生存时间为16个月。患者对KORTUC-IORT的所有治疗均耐受良好,副作用少且无严重并发症。可以确定,KORTUC-IORT的结合对于局部晚期不可切除的胰腺癌患者是安全有效的,并结合了体外放射疗法和全身化学疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号